文献速递膀胱癌与上尿路尿路上皮癌

ADXBLADDER检测与尿细胞学在非肌层浸润性膀胱癌随访中的性能比较

Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study.
PubMed 文献 · BJU Int · 2020-08-29

这项多中心前瞻性盲法研究比较了ADXBLADDER检测与尿细胞学在检测非肌层浸润性膀胱癌复发中的性能。ADXBLADDER总体敏感性为51.9%、特异性为66.4%、阴性预测值为92%,而细胞学敏感性为16.7%、特异性为98%、阴性预测值为90.7%。ADXBLADDER对低级别和高级别复发的敏感性均优于细胞学,有望成为更可靠的尿细胞学替代方法。

要点

  • ADXBLADDER检测NMIBC复发的敏感性为51.9%,高于细胞学的16.7%。
  • ADXBLADDER对低级别和高级别复发的敏感性分别为44.1%和58.8%。
  • ADXBLADDER排除高级别复发的比例为97.8%,细胞学为97.1%。

核心结论

  • ADXBLADDER检测低级别和高级别NMIBC复发的性能均优于尿细胞学。
  • ADXBLADDER有望成为NMIBC随访中比尿细胞学更可靠的替代方法。

研究设计与样本

  • 多中心前瞻性盲法研究,2017年8月至2019年7月在21个欧盟中心开展,其中14个中心收集了匹配的细胞学数据。
  • 患者在膀胱镜检查前收集尿液,进行尿细胞学和ADXBLADDER检测,并与膀胱镜诊断结果进行比较。

主要发现

  • ADXBLADDER总体敏感性51.9%、特异性66.4%、阴性预测值92%。
  • ADXBLADDER对低级别和高级别复发的敏感性分别为44.1%和58.8%。
  • 细胞学敏感性16.7%、特异性98%、阴性预测值90.7%,对低级别和高级别疾病的敏感性均为17.6%。
  • ADXBLADDER能排除97.8%的高级别复发,细胞学为97.1%。

关键数值与推荐

  • ADXBLADDER敏感性51.9%、特异性66.4%、阴性预测值92%。
  • 细胞学敏感性16.7%、特异性98%、阴性预测值90.7%。
  • ADXBLADDER对低级别复发敏感性44.1%,对高级别复发敏感性58.8%。
  • 细胞学对低级别和高级别复发敏感性均为17.6%。

临床怎么用

  • 在NMIBC随访中,ADXBLADDER可作为尿细胞学的替代或补充检测,以提高复发检出敏感性。
  • ADXBLADDER的高阴性预测值有助于排除高级别复发,但需结合膀胱镜等标准随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare directly the performance of the ADXBLADDER test with that of cytology in the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences. BACKGROUND: ADXBLADDER is a urine test based on the detection of MCM5, a DNA licensing factor expressed in all cells capable of dividing. Expression is usually restricted to the basal stem cell compartment; however, in malignancy, MCM5-expressing cells can be found throughout the epithelium. Detection of MCM5 in urine sediment can be indicative of the presence of a bladder tumour. PATIENTS AND METHODS: A multicentre prospective, blinded study was carried out from August 2017 and July 2019 at 21 European Union centres, 14 of which collected matching cytology data. Urine was collected from patients prior to cystoscopy. Urine cytology and ADXBLADDER were performed and compared to the diagnosis obtained by cystoscopy. The performance of cytology and ADXBLADDER were then compared. RESULTS: The overall performance of ADXBLADDER demonstrated a sensitivity of 51.9%, a specificity of 66.4%, and a negative predictive value (NPV) of 92%. The sensitivity of ADXBLADDER for low- and high-grade recurrences was 44.1% and 58.8%, respectively. By contrast, cytology sensitivity was 16.7%, specificity was 98% and NPV was 90.7%. Cytology sensitivity for both low- and high-grade disease was 17.6%. CONCLUSIONS: ADXBLADDER detection of both low- and high-grade NMIBC recurrence is superior to that of cytology, with ADXBLADDER able to exclude the presence of high-grade recurrence in 97.8% of cases compared to 97.1% with cytology. These results show that ADXBLADDER has promise as a more reliable alternative to urine cytology in the follow-up of NMIBC.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Gontero P, Montanari E, Roupret M, et al. Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study. BJU Int. 2020. PMID: 32745350. doi:10.1111/bju.15194

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。